This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Publications

Journal highlights March/April on state of the art of HDL in the management of ASCVD

Tuesday 7 May 2019   (0 Comments)
Share |

In our regular feature, Editor-in-Chief Arnold von Eckardstein highlights interesting articles from recent issues of Atherosclerosis journal. The highlights are an easy way for you to get an overview of the issue content every month.

The March and April issues of Atherosclerosis contain several articles, which discuss the state of the art of HDL in the management of ASCVD and describe novel approaches to exploit the anti-atherogenic properties of HDL for diagnostics and treatment.

Because of the inverse association between HDL cholesterol and risk of atherosclerotic cardiovascular disease (ASCVD) in many epidemiological studies, as well as many protective likely anti-atherogenic properties of HDL in vitro and in vivo, HDL has been pursued for a long time as a therapeutic target in cardiovascular medicine. Futile intervention trials as well as lack of genetic causality shed doubt on the suitability of HDL-cholesterol as a therapeutic target. 

To the journal highlights March/April>>

To the March issue of Atherosclerosis>>

To the April issue of Atherosclerosis>>

Atherosclerosis is now present on Facebook (Atherosclerosis - Journal of the European Atherosclerosis Society) and Twitter (@ATHjournal). Join our social media community and follow us!

Membership Software Powered by YourMembership  ::  Legal